An open label,multicenter study to evaluate the effect of Nimotuzumab in combination with chemotherapy and/or radiotherapy in patients with head and neck cancer
Latest Information Update: 30 Jun 2017
Price :
$35 *
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biocon
- 30 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology